SCHEMBL2701632

SCHEMBL2701632

Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1C(=O)OCc1ccccc1)C(=O)N([C@H]1CCN(C(=O)OC(C)(C)C)C1)C2

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 1/20 0.39
▸ USP30 Q70CQ3 2/20 0.39
▸ DPP4 P27487 4/20 0.37
▸ TRPC3 Q13507 1/20 0.37
▸ TRPC7 Q9HCX4 1/20 0.37
▸ MDM2 Q00987 1/20 0.36
▸ TP53 P04637 2/20 0.36
▸ JAK2 O60674 1/20 0.36
▸ JAK1 P23458 1/20 0.36
▸ CYP3A4 P08684 2/20 0.36
▸ CYP2C19 P33261 2/20 0.36
▸ DPP8 Q6V1X1 1/20 0.36
▸ DPP9 Q86TI2 1/20 0.36
▸ MAPK8 P45983 2/20 0.36
▸ POLB P06746 1/20 0.35
▸ PARP1 P09874 1/20 0.35
▸ GPBAR1 Q8TDU6 1/20 0.35
▸ EGFR P00533 1/20 0.35
▸ SRC P12931 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2701634 1.00 GPR119 (0.39) GPR119USP30DPP4TRPC3TRPC7
SCHEMBL2706200 0.97 TP53 (0.40) GPR119DPP4TRPC3TRPC7TP53
SCHEMBL2705021 0.89 DPP4 (0.41) USP30DPP4MDM2TP53DPP8
SCHEMBL2705023 0.89 DPP4 (0.41) USP30DPP4MDM2TP53DPP8
SCHEMBL8446881 0.86 TRPC3 (0.38) DPP4TRPC3TRPC7CYP3A4CYP2C19
SCHEMBL2704020 0.85 DPP4 (0.43) DPP4MDM2TP53DPP8DPP9
SCHEMBL2705049 0.84 DPP4 (0.39) DPP4CYP3A4CYP2C19DPP8DPP9
SCHEMBL2702835 0.84 DPP4 (0.39) DPP4CYP3A4CYP2C19DPP8DPP9
SCHEMBL2703644 0.84 DPP4 (0.39) DPP4CYP3A4CYP2C19DPP8DPP9
SCHEMBL4404834 0.83 DPP4 (0.44) USP30DPP4MDM2TP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1888589-B1 PYRROLOPYRIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS BRISTOL MYERS SQUIBB CO (US) 2012-05-09 — — EP disclosed
EP-1888589-B1 PYRROLOPYRIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS BRISTOL MYERS SQUIBB CO (US) 2012-05-09 — — EP disclosed
US-7521557-B2 Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods BRISTOL-MYERS SQUIBB COMPANY (US) 2009-04-21 — — US disclosed
US-7521557-B2 Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods BRISTOL-MYERS SQUIBB COMPANY (US) 2009-04-21 — — US disclosed
US-7521557-B2 Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods BRISTOL-MYERS SQUIBB COMPANY (US) 2009-04-21 — — US disclosed
US-20060264457-A1 Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods BRISTOL-MYERS SQUIBB COMPANY 2006-11-23 — — US disclosed
US-20060264457-A1 Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods BRISTOL-MYERS SQUIBB COMPANY 2006-11-23 — — US disclosed
US-20060264457-A1 Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods BRISTOL-MYERS SQUIBB COMPANY 2006-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264457-A1 Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods DPP4, DPP9, DPP3 GPR119 123/4885USP30 3167/4885DPP4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback